Neoadjuvant chemotherapy is increasingly used in breast cancer, especially for
downstaging the primary tumor in the breast and the metastatic axillary lymph node …

In this analysis, the role of metabolic imaging with fluorine 18 fluorodeoxyglucose (FDG) in
breast cancer is reviewed. The analysis was limited to recent works by using state-of-the-art …

Purpose The aim of this study was to determine the impact of the main clinicopathological
and biological prognostic factors of breast cancer on 18 F-fluorodeoxyglucose (FDG) uptake …

Introduction. This study compared the diagnostic test accuracy of magnetic resonance
imaging (MRI) with that of 18F-fluoro-2-glucose-positron emission tomography/computed …

Multimodality imaging, as represented by its greatest exponent, PET/CT, has a firm place in
the evaluation of a patient presenting with cancer. With 18F-FDG, PET/CT is rapidly …

Molecular imaging receives increased attention for selecting patients who will benefit from
targeted anticancer therapies. Neo-ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab …

Background An effective and well tolerated treatment is needed for patients with early HER2-
positive breast cancer who do not achieve a pathological complete response after …

Clinical evidence regarding the value of 18 F-FDG PET for therapy responses assessment in
breast cancer is increasing. The objective of this study is to evaluate the accuracy of 18 F …

Approximately 8–20% of breast cancer patients receiving neoadjuvant chemotherapy fail to
achieve a measurable response and endure toxic side effects without benefit. Most clinical …

Neoadjuvant chemotherapy (NAC) involves administration of chemotherapeutic agents to
patients with newly diagnosed breast cancer prior to definitive surgical treatment …